Starting patients on Levemir® (insulin detemir [rDNA origin] injection)

Starting dose: When initiating Levemir® (insulin detemir [rDNA origin] injection), start insulin-naïve patients with type 2 diabetes on 10 units once daily or 0.1 to 0.2 units/kg daily with the evening meal or at bedtime and titrate accordingly.1

Titration after assessing mean 3-Day FPG (mg/dL)

Physician-directed patient self-titration*: For patients taking Levemir® once daily, the dose can be adjusted to reach FPG goals: 70-90 mg/dL or 80-110 mg/dL, as seen in the TITRATE study.2

Dose Adjustments: Can be made every third day based on an average of 3 consecutive FPG values.

*Clinical judgment should be used for dose adjustments and to account for hypoglycemia. The dose of Levemir® should be adjusted to achieve glycemic targets.

The TITRATE study was exclusively once-daily treatment with Levemir® (insulin detemir [rDNA origin] injection) in patients with type 2 diabetes2

  • Majority of patients achieved the ADA–recommended target of A1C <7%2,3
  • Average insulin doses at the end of trial: 0.57 units/kg (70-90 mg/dL group) and 0.51 units/kg (80-110 mg/dL group)2
  • Low rates of hypoglycemia2
    • Non severe hypoglycemia rates were 5.09 (70-90 mg/dL) and 3.16 (80-110 mg/dL) per patient-year
    • A single major hypoglycemic event was reported in the 70 to 90 mg/dL group; no major hypoglycemic events were reported in the 80 to 110 mg/dL group*

*Minor= SMPG <56 mg/dL and not requiring third-party assistance.
Major= requiring third-party assistance.

Unit-to-unit conversion from insulin glargine to Levemir® (insulin detemir [rDNA origin] injection)

Converting patients is simple.When converting from insulin glargine, convert unit to unit to Levemir® (insulin detemir [rDNA origin] injection). However, some patients with type 2 diabetes may require more Levemir® than NPH insulin, as observed in 1 trial1